We are live on ! Find out more
EU

Emory University Portfolio holdings

AUM $267M
1-Year Est. Return 48.26%
This Fund
S&P 500
This Quarter Est. Return
+16.9%
1 Year Est. Return
+48.26%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$126M
AUM Growth
+$13.2M
Cap. Flow
+$877K
Cap. Flow %
0.69%
Top 10 Hldgs %
43.94%
Holding
59
New
7
Increased
24
Reduced
19
Closed
7

Top Buys

Rank Stock Value
1
PBYI icon
Puma Biotechnology
PBYI
+$1.91M
2
TSRO
TESARO, Inc.
TSRO
+$1.8M
3
RXDX
Ignyta, Inc.
RXDX
+$1.76M
4
BHVN
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
+$1.76M
5
BKR icon
Baker Hughes
BKR
+$1.7M

Top Sells

Rank Stock Value
1
LOXO
Loxo Oncology, Inc
LOXO
+$2.74M
2
NXTM
NxStage Medical Inc.
NXTM
+$1.8M
3
AWI icon
Armstrong World Industries
AWI
+$1.65M
4
SRPT icon
Sarepta Therapeutics
SRPT
+$1.58M
5
AXTA icon
Axalta
AXTA
+$1.58M

Sector Composition

Rank Sector Weight
1 Healthcare 46.68%
2 Financials 30.76%
3 Technology 5.34%
4 Consumer Discretionary 5.22%
5 Energy 4.09%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
BRK.A icon
1
Berkshire Hathaway Class A
BRK.A
$1.06T
$32.1M 25.44%
117
– –
ZGNX
2
DELISTED
Zogenix, Inc.
ZGNX
$5.13M 4.06%
146,257
+27,938
+24% +$379K
PBYI icon
3
Puma Biotechnology
PBYI
$434M
$2.46M 1.95%
+20,555
New +$1.91M
MYOV
4
DELISTED
Myovant Sciences Ltd.
MYOV
$2.43M 1.93%
157,303
+28,075
+22% +$341K
ALNY icon
5
Alnylam Pharmaceuticals
ALNY
$35.7B
$2.43M 1.92%
20,660
-922
-4% -$78.7K
ONC
6
BeOne Medicines Ltd
ONC
$32.4B
$2.39M 1.89%
23,061
-18,248
-44% -$1.36M
ASND icon
7
Ascendis Pharma A/S
ASND
$17.1B
$2.17M 1.72%
59,876
+421
+0.7% +$12.1K
BHVN
8
DELISTED
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
$2.17M 1.71%
+57,938
New +$1.76M
RXDX
9
DELISTED
Ignyta, Inc.
RXDX
$2.11M 1.67%
+170,507
New +$1.76M
WVE icon
10
Wave Life Sciences
WVE
$1.12B
$2.09M 1.66%
96,222
+22,202
+30% +$446K
FOLD
11
DELISTED
Amicus Therapeutics
FOLD
$2M 1.58%
132,479
-69,878
-35% -$924K
ACAD icon
12
Acadia Pharmaceuticals
ACAD
$4.38B
$2M 1.58%
52,977
-3,946
-7% -$128K
SGEN
13
DELISTED
Seagen Inc. Common Stock
SGEN
$1.96M 1.55%
35,982
+12,278
+52% +$629K
BCRX icon
14
BioCryst Pharmaceuticals
BCRX
$2.36B
$1.89M 1.49%
360,042
+72,492
+25% +$371K
TSRO
15
DELISTED
TESARO, Inc.
TSRO
$1.88M 1.48%
+14,529
New +$1.8M
NBIX icon
16
Neurocrine Biosciences
NBIX
$17.2B
$1.87M 1.48%
30,482
+1,166
+4% +$61.5K
BMRN icon
17
BioMarin Pharmaceuticals
BMRN
$11.5B
$1.84M 1.46%
19,783
+2,453
+14% +$217K
TVTX icon
18
Travere Therapeutics
TVTX
$5.27B
$1.84M 1.46%
73,917
-17,191
-19% -$379K
LJPC
19
DELISTED
La Jolla Pharmaceutical Company
LJPC
$1.83M 1.45%
52,754
+5,401
+11% +$174K
TRN icon
20
Trinity Industries
TRN
$2.9B
$1.83M 1.45%
+79,716
New +$1.65M
BKR icon
21
Baker Hughes
BKR
$55.5B
$1.76M 1.39%
+48,027
New +$1.7M
SMC
22
Summit Midstream
SMC
$407M
$1.75M 1.39%
5,837
– –
NGNE icon
23
Neurogene
NGNE
$744M
$1.75M 1.38%
6,163
+872
+16% +$250K
GBT
24
DELISTED
Global Blood Therapeutics, Inc.
GBT
$1.74M 1.38%
56,157
+3,448
+7% +$97K
WBC
25
DELISTED
WABCO HOLDINGS INC.
WBC
$1.74M 1.38%
11,781
-1,166
-9% -$162K
1
2 3

Similar funds

CFG
Cambridge Financial Group Columbus, Ohio $267M AUM 31.62% 1-Year Est. Return
PC
Packer & Co Cottesloe, Australia $267M AUM
ALC
Alexander Labrunerie & Co Columbia, Missouri $267M AUM 21.24% 1-Year Est. Return
TWM
TCFG Wealth Management Laguna Niguel, California $267M AUM 39.78% 1-Year Est. Return
IP
Indigo Partners Phoenix, Arizona $267M AUM 9% 1-Year Est. Return
SP
ShawSpring Partners Boston, Massachusetts $268M AUM 28.19% 1-Year Est. Return
EAIC
Empower Annuity Insurance Company Hartford, Connecticut $268M AUM 0.28% 1-Year Est. Return
STB
S&T Bank Indiana, Pennsylvania $268M AUM 39.92% 1-Year Est. Return

Emory University's Q3 2017 Portfolio in Review

As of Q3 2017, Emory University held 59 positions worth $126M, up 12% from $113M the previous quarter. Its ten largest holdings account for 44% of the portfolio.

Emory University's Q3 2017 filing shows 7 new, 24 increased, 19 reduced and 7 closed positions. Its largest new stake was Puma Biotechnology: 20,555 shares worth $2.46M. The largest sale was Loxo Oncology, Inc, an estimated $2.74M.

By sector, the portfolio is most concentrated in Healthcare at 47% of assets, up from 44% a quarter earlier, followed by Financials and Technology.

  • Emory University's largest Q3 2017 buy was Puma Biotechnology: 20,555 shares worth $2.46M.
  • Emory University added most to Ra Pharmaceuticals, Inc. Common Stock in Q3 2017, an estimated $740K increase.
  • Emory University's biggest Q3 2017 reduction was BeOne Medicines Ltd, cutting an estimated $1.36M.
  • Emory University fully exited Loxo Oncology, Inc in Q3 2017, selling an estimated $2.74M.
  • Emory University's ten largest holdings make up 44% of its $126M portfolio in Q3 2017.
  • Emory University opened 7 new positions and closed 7 in Q3 2017.
  • Emory University's portfolio value rose 12% quarter-over-quarter to $126M.

Based on Emory University's 13F filing for Q3 2017, filed 14 Nov 2017.